This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

First in Human Study of NI-0701 in Healthy Volunteers

This study has been completed.
Information provided by:
NovImmune SA Identifier:
First received: December 6, 2010
Last updated: NA
Last verified: December 2010
History: No changes posted
The purpose of this study is to determine the safety, pharmacodynamic and pharmacokinetic profiles of a novel therapeutic drug when administered to healthy volunteers.

Condition Intervention Phase
Healthy Volunteers Drug: NI-0701 Drug: Placebo Phase 1

Study Type: Interventional
Official Title: A First in Man Randomized Placebo Controlled Study of Single Ascending Intravenous Doses of NI-0701 in Healthy Volunteers

Further study details as provided by NovImmune SA:

Primary Outcome Measures:
  • Safety and tolerability of escalating single IV doses of NI-0701 in healthy volunteers

Secondary Outcome Measures:
  • NI-0701 Pharmacokinetic parameters in healthy volunteers
  • NI-0701 plasma pharmacodynamic effects upon NI-0701 single intravenous infusion
  • Pharmacodynamic effects of NI-0701 on Histamine skin-induced wheal and flare
  • Immunogenicity of NI-0701

Arms Assigned Interventions
Experimental: NI-0701 Drug: NI-0701
Placebo Comparator: Placebo Drug: Placebo


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Non smokers
  • Able to adhere to study visits and protocol requirements

Exclusion Criteria:

  • Any clinical safety laboratory measurements value > Grade 1 on WHO Toxicity Scale
  • Established or recurrent history of allergic reactions
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01255501

United Kingdom
London, United Kingdom
Sponsors and Collaborators
NovImmune SA
Principal Investigator: John Lambert, MD PXL
  More Information Identifier: NCT01255501     History of Changes
Other Study ID Numbers: NI-0701-01
Study First Received: December 6, 2010
Last Updated: December 6, 2010 processed this record on August 16, 2017